SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
SWTX/Financials
Wall Street · Earnings · Institutional Sentiment
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about SpringWorks Therapeutics, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | -1.2700 | -1.367 | 0 | 21 | -54 | 0.91 | -59 | 0.87 | -59 | 0.08 | 16 | 256 |
| 2021 | -1.0200 | -3.113 | 35 | 0.00 | -44 | -128 | -45 | -127 | -46 | -128 | 29 | 0.00 |
| 2023 | -5.1400 | -4.919 | 6 | 1 | -274 | -319 | -280 | 0.20 | -276 | 0.20 | 134 | 12 |
| 2024 | -5.1500 | -3.318 | 5 | 195 | -325 | -209 | -341 | -39 | -343 | -39 | 197 | 2,380 |
| 2025 | - | -1.821 | - | 382 | - | -120 | - | -76 | - | -76 | - | 4,661 |
| 2026 | - | -0.443 | - | 617 | - | 2.F5X | - | 2.F51 | - | 2.F511 | - | 2.F511 |
| 2027 | - | 3.560 | - | 1,162 | - | 1.F6X | - | 1.F61 | - | 1.F611 | - | 1.F611 |
| 2028 | - | -0.940 | - | 584 | - | 0.F7X | - | 0.F71 | - | 0.F711 | - | 0.F711 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Price Target Consensus
-85.624% $31.21 · MISS
Nov. 6, 2024Price Then
$31.59
Price Target
$67.66
Price Now
$36.45